Pembrolizumab Efficacy Across Solid Tumors and Hematologic Malignancies
Pembrolizumab demonstrates proven efficacy across multiple solid tumors, with FDA approvals spanning urothelial carcinoma, non-small cell lung cancer, melanoma, gastric/gastroesophageal cancer, colorectal cancer, head and neck cancer, renal cell carcinoma, endometrial carcinoma, and several biomarker-defined indications including MSI-H/dMMR and TMB-high tumors.
Urothelial Carcinoma
For advanced urothelial carcinoma, pembrolizumab has Category 1 evidence as second-line therapy after platinum-based chemotherapy 1. The phase III trial demonstrated superior median OS of 10.3 versus 7.4 months compared to chemotherapy (P=0.002), with significantly fewer grade 3-5 adverse events (15.0% vs 49.4%) 1.
For first-line therapy, pembrolizumab is restricted to specific populations:
- Cisplatin-ineligible patients with PD-L1 CPS ≥10
- Patients ineligible for any platinum-containing chemotherapy regardless of PD-L1 status
This restriction followed FDA safety alerts showing decreased survival with first-line pembrolizumab monotherapy versus platinum-based chemotherapy in broader populations 1.
Non-Small Cell Lung Cancer
Pembrolizumab is FDA-approved for first-line treatment of metastatic NSCLC with PD-L1 TPS ≥50% without EGFR or ALK mutations 2. The phase III trial showed median PFS of 10.3 versus 6.0 months compared to chemotherapy (HR 0.5, P<0.001), with 6-month OS rate of 80.2% versus 72.4% 2.
For second-line therapy, pembrolizumab is approved for patients with PD-L1 TPS ≥1% who progressed after platinum-containing chemotherapy 2, 3. Median OS was significantly longer with pembrolizumab versus docetaxel (HR 0.71 for 2 mg/kg dose, P=0.001) 2.
Pembrolizumab plus carboplatin and pemetrexed is approved for first-line non-squamous NSCLC regardless of PD-L1 status 2. The combination showed median PFS of 19.0 versus 8.9 months compared to chemotherapy alone (HR 0.54, P=0.007) 2.
Melanoma
For stage III melanoma, pembrolizumab is a Category 1 adjuvant option for patients with clinically detected nodal metastases 4. Based on KEYNOTE-054, it is also Category 1 for clinically occult disease with stage IIIA (≥1 nodal metastasis >1 mm) or stage IIIB/C per AJCC 7th edition 4.
For patients with in-transit metastases or resected stage IV disease, pembrolizumab remains a Category 2A option 4. The panel considers pembrolizumab and nivolumab equivalent in efficacy and safety for adjuvant treatment 4.
Gastric and Gastroesophageal Cancer
For MSI-H/dMMR gastric cancer, pembrolizumab demonstrates remarkable efficacy 5. Among 42 gastric cancer patients in KEYNOTE-158, the ORR was 31% 5. In KEYNOTE-059,4 of 7 MSI-H patients achieved objective response (ORR 57.1%), with median OS not reached 5.
In KEYNOTE-061, MSI-H patients receiving pembrolizumab had median OS not reached versus 8.1 months with paclitaxel, with median PFS of 17.8 versus 3.5 months 5.
For HER2-negative gastric cancer, nivolumab plus chemotherapy is preferred over pembrolizumab based on CheckMate-649 results showing superior outcomes 5.
Colorectal Cancer
Pembrolizumab is recommended as first-line therapy for MSI-H or dMMR metastatic colorectal cancer 6. KEYNOTE-177 demonstrated improved PFS (HR 0.60,95% CI 0.45-0.80) with significantly lower grade ≥3 adverse events compared to chemotherapy 6.
Critical caveat: The ORR was not significantly different between pembrolizumab and chemotherapy, and 29% of pembrolizumab patients experienced progressive disease versus 12% with chemotherapy 6.
Pembrolizumab is NOT recommended for MSS/pMMR colorectal cancer with high TMB (≥10 mutations/Mb) 6. Retrospective analysis showed no benefit in patients with high TMB and pMMR or without pathogenic polymerase mutations 6.
Head and Neck Cancer
Pembrolizumab may be offered for TMB-high (≥10 mutations/Mb) recurrent or metastatic rare head and neck cancers 7. KEYNOTE-158 showed ORR of 29% in TMB-high tumors versus 6% in non-TMB-high tumors 7.
For PD-L1-positive (≥1%) advanced salivary gland cancers, pembrolizumab showed 12% ORR in KEYNOTE-028 7. However, only 23% of screened salivary gland cancers were PD-L1-positive 7.
Renal Cell Carcinoma
Pembrolizumab plus axitinib is approved for first-line advanced RCC 8. KEYNOTE-426 demonstrated efficacy across IMDC risk categories, with treatment continuing up to 24 months for pembrolizumab 8.
Endometrial Carcinoma
For pMMR/non-MSI-H endometrial carcinoma, pembrolizumab plus lenvatinib showed significant benefit 8. KEYNOTE-775 demonstrated median OS of 17.4 versus 12.0 months (HR 0.68, P=0.0001) and median PFS of 6.6 versus 3.8 months (HR 0.60, P<0.0001) compared to chemotherapy 8.
For MSI-H/dMMR endometrial carcinoma, pembrolizumab monotherapy is approved 8. KEYNOTE-158 showed 46% ORR with 12% complete response rate, with median duration of response not reached 8.
Biomarker-Defined Indications
MSI-H/dMMR Tumors (Tissue-Agnostic)
Pembrolizumab is FDA-approved for unresectable or metastatic MSI-H/dMMR solid tumors that have progressed after prior treatment 5, 6, 7, 9. This approval is based on KEYNOTE-158, which enrolled 233 patients across multiple tumor types, showing 34.3% ORR with median OS of 23.5 months 7, 9.
TMB-High Tumors (≥10 mutations/Mb)
Pembrolizumab is approved for TMB-high (≥10 mutations/Mb) metastatic solid tumors that have progressed after prior treatment with no satisfactory alternatives 7, 8. KEYNOTE-158 showed 29% ORR in 102 TMB-high patients, with 57% maintaining response ≥12 months 8.
Important limitation: No gastroesophageal cancer patients were included in the TMB analysis 5, and the benefit does not extend to colorectal cancer with pMMR 6.
Hematologic Malignancies
Pembrolizumab is FDA-approved for relapsed/refractory classical Hodgkin lymphoma 10. The anti-PD-1 approach capitalizes on the unique biology of cHL, where extensive immune infiltrate surrounds rare tumor cells 10.
Key Clinical Considerations
PD-L1 testing requirements vary by indication:
- NSCLC: TPS ≥50% for first-line monotherapy, ≥1% for second-line 2, 3
- Urothelial: CPS ≥10 for first-line cisplatin-ineligible 1
- Gastric: CPS ≥5 for nivolumab combinations 5
Common pitfall: Different PD-L1 assays (22C3, 28-8) and scoring methods (TPS vs CPS) are used across indications, and results may not be directly comparable 9.
Treatment duration: Pembrolizumab is typically administered for maximum 24 months (35 cycles) in most indications 8, though treatment may continue beyond progression if clinically stable and deriving benefit 8.
Safety profile: Grade ≥3 adverse events are consistently lower with pembrolizumab monotherapy versus chemotherapy across indications 1, 2. However, combination with lenvatinib significantly increases toxicity risk, particularly thyroid dysfunction 8, 11.